InsiderSignal.AI

InsiderSignal.ai

LLY - Eli Lilly & Co

Insider Purchase by Van Naarden Jacob (EVP, Pres, Lilly Oncology)

1 Year
After Trade
Before Trade

Loading data...

Trade Summary

6 months ago, Van Naarden Jacob, serving as EVP, Pres, Lilly Oncology at Eli Lilly & Co (LLY), purchased 1,000 shares at $647.36 per share, for a total transaction value of $647,360.00. Following this transaction, Van Naarden Jacob now holds 29,206 shares of LLY.

This purchase represents a 4.00% increase in Van Naarden Jacob's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Wednesday, August 13, 2025 and publicly disclosed via SEC Form 4 filing on Wednesday, August 13, 2025, meaning the disclosure happened on the same day as the trade.

Eli Lilly & Co operates in the HEALTHCARE sector, specifically within the DRUG MANUFACTURERS - GENERAL industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Van Naarden Jacob

EVP, Pres, Lilly Oncology

Jacob S. Van Naarden (also known as Jake Van Naarden) is Executive Vice President and President of Lilly Oncology at Eli Lilly and Company, where he oversees all aspects of oncology from discovery through commercial operations.[[1]](https://www.lilly.com/about/leadership/jacob-van-naarden)[[2]](https://assets.ctfassets.net/srys4ukjcerm/2OXmY4sTeGLnOyUoabewyX/4aea6d1b90caee7d9b58bad017687c3d/2024_07_19VanNaardenPrintable.pdf) He also serves as head of corporate business development.[[1]](https://www.lilly.com/about/leadership/jacob-van-naarden) Van Naarden joined Lilly in 2019 following the company's acquisition of Loxo Oncology, Inc., where he was Chief Operating Officer, and subsequently played a key role in establishing the oncology research and development program.[[1]](https://www.lilly.com/about/leadership/jacob-van-naarden)[[2]](https://assets.ctfassets.net/srys4ukjcerm/2OXmY4sTeGLnOyUoabewyX/4aea6d1b90caee7d9b58bad017687c3d/2024_07_19VanNaardenPrintable.pdf)[[3]](https://assets.ctfassets.net/srys4ukjcerm/cAGy7hZkAaMKEI3sFplEY/4cb5d087d2362916c302d640b976515a/2022_06_22VanNaardenPrintable.pdf) Prior to Loxo Oncology, Van Naarden held positions in biotechnology investing, operations, and advisory roles at HealthCor Management, Aisling Capital, and Goldman Sachs.[[1]](https://www.lilly.com/about/leadership/jacob-van-naarden)[[2]](https://assets.ctfassets.net/srys4ukjcerm/2OXmY4sTeGLnOyUoabewyX/4aea6d1b90caee7d9b58bad017687c3d/2024_07_19VanNaardenPrintable.pdf)[[5]](https://www.marketscreener.com/insider/JACOB-VAN-NAARDEN-A0PILA/) He earned an A.B. degree in molecular biology from Princeton University.[[1]](https://www.lilly.com/about/leadership/jacob-van-naarden)[[2]](https://assets.ctfassets.net/srys4ukjcerm/2OXmY4sTeGLnOyUoabewyX/4aea6d1b90caee7d9b58bad017687c3d/2024_07_19VanNaardenPrintable.pdf) In 2023, his total compensation at Eli Lilly was reported as $4,886,520.[[4]](https://www.erieri.com/executive/salary/jacob-van-naarden-a05c)

View full insider profile →

Trade Price

$647.36

Quantity

1,000

Total Value

$647,360.00

Shares Owned

29,206

Trade Date

Wednesday, August 13, 2025

193 days ago

SEC Filing Date

Wednesday, August 13, 2025

HEALTHCAREDRUG MANUFACTURERS - GENERAL

About Eli Lilly & Co

Company Overview

No company information available
View news mentioning LLY

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/125626

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime